Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes

By Julia K Rohr, Prudence Ive, Charles Robert Horsburgh, Rebecca Berhanu, Christopher J Hoffmann, Robin Wood, Andrew Boulle, Janet Giddy, Hans Prozesky, Michael Vinikoor, Mwanza wa Mwanza, Giles Wandeler, Mary-Ann Davies  Matthew Fox  |  | 

After first-line ART failure, the importance of change in nucleoside reverse transcriptase inhibitor (NRTI) in second line is uncertain due to the high potency of protease inhibitors used in second line. Our assessment of clinical data from 6290 adult patients in South Africa and Zambia found that changing NRTI in second line was associated with better clinical outcomes in South Africa.

Publication details

Journal of Acquired Immune Deficiency Syndromes
#77
2018
413
https://www.ncbi.nlm.nih.gov/pubmed/29206723